Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a sell rating to a hold rating in a research report report published on Wednesday.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Oramed Pharmaceuticals in a research note on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 2.1 %

Shares of Oramed Pharmaceuticals stock opened at $2.40 on Wednesday. Oramed Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $3.67. The stock has a market capitalization of $96.75 million, a price-to-earnings ratio of 21.82 and a beta of 1.70. The business’s 50 day simple moving average is $2.37 and its 200-day simple moving average is $2.39.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Murchinson Ltd. grew its holdings in Oramed Pharmaceuticals by 23.2% in the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after buying an additional 320,495 shares in the last quarter. BML Capital Management LLC raised its stake in shares of Oramed Pharmaceuticals by 62.1% during the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after purchasing an additional 837,153 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Oramed Pharmaceuticals in the third quarter worth about $272,000. Dimensional Fund Advisors LP lifted its holdings in Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares during the period. Finally, XTX Topco Ltd bought a new position in Oramed Pharmaceuticals in the 2nd quarter valued at about $40,000. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.